MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.31
-3.08
-5.27%
After Hours: 57.79 +2.48 +4.48% 19:00 02/25 EST
OPEN
55.04
PREV CLOSE
58.39
HIGH
57.99
LOW
53.96
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
71.25
52 WEEK LOW
15.19
MARKET CAP
7.56B
P/E (TTM)
-58.2088
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference
SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, ...
GlobeNewswire · 3h ago
Global Poe Injector Market Trends 2021, Share, Size, Growth Rate, Key Regions with Industry Research and Scope, Impact of COVID-19, Risk and Challenges 2025
Feb 25, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" Global “Poe Injector Market” report has...
The Express Wire · 18h ago
Adaptive Biotechnologies: Q4 Earnings Insights
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 94.12% year over year to ($0.33), which missed the estimate of ($0.29). Revenue of $30,185,0...
Benzinga · 1d ago
10-K: ADAPTIVE BIOTECHNOLOGIES CORP
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
BRIEF-Adaptive Biotechnologies Reports Q4 And Full Year 2020 Financial Results
reuters.com · 1d ago
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results
SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products t...
GlobeNewswire · 1d ago
Adaptive Bio Launches T-Cell Based COVID-19 Tests
Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection. T-Detect is currently under review by the FDA for Emergency Use Authorization. Separately, the Company also expanded its c...
Benzinga · 2d ago
T-Cell Screening Launched to Detect Prior Covid Infections
Adaptive Biotechnologies Corp. launched a test that uses machine-learning technology from Microsoft Corp. to detect prior Covid-19 infections, aiming to fill an important gap left by standard antibody screening.
Bloomberg · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADPT. Analyze the recent business situations of Adaptive Biotechnologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADPT stock price target is 62.60 with a high estimate of 74.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 336
Institutional Holdings: 113.60M
% Owned: 83.06%
Shares Outstanding: 136.77M
TypeInstitutionsShares
Increased
80
9.40M
New
72
237.65K
Decreased
78
7.00M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
Chad Robins
President
Julie Rubinstein
Co-Founder/Chief Scientific Officer
Harlan Robins
Chief Financial Officer
Chad Cohen
Senior Vice President/General Manager
.. Willis
Chief Operating Officer
Mark Adams
Chief Human Resource Officer
Francis Lo
Senior Vice President/General Counsel
Stacy Taylor
Senior Vice President
Sharon Benzeno
Senior Vice President
Nancy Hill
Senior Vice President
Jyoti Palaniappan
Senior Vice President
Charles Snag
Other
Lance Baldo
Other
Sean Nolan
Lead Director/Independent Director
Peter Neupert
Independent Director
Kevin Conroy
Independent Director
Eric Dobmeier
Independent Director
David Goel
Independent Director
Michelle Griffin
Independent Director
Robert Hershberg
Independent Director
Michael Pellini
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ADPT
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.